Trevor Lawley is a co-founder and Chief Scientific Officer of Microbiotica. He is also Faculty Group Leader of the Host-Microbiota Interactions Team at the Wellcome Trust Sanger Institute (WTSI), where his research uses advanced metagenomic sequencing and deep culturing to investigate the microbial communities contained on and within-host organisms that are associated with health and a range of diseases and syndromes such as infections, autoimmunity, irritable bowel syndromes, and cancer.
He has pioneered many aspects of the bacteriotherapy concept where defined mixtures of bacteria are used to cure intestinal diseases linked to pathological imbalances in the intestinal microbiota. Trevor began his research at WTSI in 2007 as a Post-Doctoral Fellow in the Microbial Pathogenesis group, having received a Royal Society Fellowship to start a new research program in C. difficile epidemiology and pathogenesis. During this time, he has worked with a global consortium from over 25 institutes to assemble a comprehensive C. difficile culture collection, now housed within the Sanger Institute.